Immunovant, Inc. (NASDAQ: IMVT) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
Immunovant price target lowered to $45 from $47 at Wells Fargo [Yahoo! Finance]
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth [Yahoo! Finance]
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Wells Fargo & Company from $47.00 to $45.00. They now have an "overweight" rating on the stock.
FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial [Yahoo! Finance]